The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Incidence of central nervous system metastases (mCNS) and overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation followed by durvalumab (Durva).
 
John Sharp
No Relationships to Disclose
 
Songzhu Zhao
No Relationships to Disclose
 
Sandip Patel
No Relationships to Disclose
 
Lai Wei
No Relationships to Disclose
 
Mingjia Li
No Relationships to Disclose
 
Jeremy Brownstein
Honoraria - AstraZeneca; DAVA Pharmaceuticals
 
Meng Xu WELLIVER
Consulting or Advisory Role - Lilly; Lilly; Novocure; Novocure
Travel, Accommodations, Expenses - Novocure
 
Karl Haglund
No Relationships to Disclose
 
Joshua David Palmer
Honoraria - American Society for Radiation Oncology; Novocure; Varian Medical Systems
Consulting or Advisory Role - Huron Consulting; More Health
Research Funding - Kroger; Varian Medical Systems
Travel, Accommodations, Expenses - American Society for Radiation Oncology; Novocure
 
Sasha Beyer
No Relationships to Disclose
 
Raju R. Raval
No Relationships to Disclose
 
Peter G. Shields
No Relationships to Disclose
 
Kai He
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Geneplus; Iovance Biotherapeutics; Lyell Immunopharma; Mirati Therapeutics; Perthera
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst); Oncoc4 (Inst)
 
Jacob Kaufman
Consulting or Advisory Role - AstraZeneca
 
Regan Michelle Memmott
Consulting or Advisory Role - Takeda
 
Asrar Alahmadi
No Relationships to Disclose
 
David Paul Carbone
Employment - James Cancer Center
Honoraria - AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Bristol-Myers Squibb; Curio Science; EMD Serono; Genentech/Roche; GlaxoSmithKline; Intellisphere; InThought; Iovance Biotherapeutics; Janssen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Merck KGaA; Mirati Therapeutics; MSD Oncology; NCCN/AstraZeneca; Novartis; OncLive/MJH Life Sciences; Pfizer; PPD; Regeneron; Roche; Sanofi
 
Gregory Alan Otterson
Consulting or Advisory Role - Novocure; OncLive/MJH Life Sciences
Research Funding - Apollomics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst)
 
Carolyn J Presley
Consulting or Advisory Role - Jazz Pharmaceuticals; Jazz Pharmaceuticals; Onc Live; Regeneron
 
Dwight Hall Owen
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Onc.AI (Inst); Palobiofarma (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech